Enzalutamide Active in Low-, Intermediate-Risk Prostate Cancer - HealthDay News
6/27/2022 12:00:00 AM2 years 10 months ago
by Physician’s Briefing Staff
by Physician’s Briefing Staff
Significant reduction seen in risk of prostate cancer progression for enzalutamide plus AS versus active surveillance alone
MONDAY, June 27, 2022 (HealthDay News) -- For patients with low- or intermediate-risk localized prostate cancer, enzalutamide monotherapy plus active surveillance (AS) is well tolerated and induces a… [+1672 chars]
full article...